Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 3Other hematologic neoplasm 2Gastrointestinal 2Myeloid 1

Conditions

Cholangiocarcinoma 2Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Glioblastoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 54Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × olutasidenib × Gastrointestinal × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡